Genetic Changes in Malignant Fibrous Histiocytoma and Their Impact on Survival
Author Information
Author(s): Weng W-H, Åhlén J, Lui W-O, Brosjö O, Pang S-T, von Rosen A, Auer G, Larsson O, Larsson C
Primary Institution: Karolinska Hospital
Hypothesis
Gain of chromosome 17q in malignant fibrous histiocytoma is associated with better survival outcomes.
Conclusion
Patients with gain of 17q in their malignant fibrous histiocytoma tumors had significantly improved disease-free survival and a lower risk of metastasis.
Supporting Evidence
- Gain of 17q was significantly associated with longer overall survival.
- Patients with four or more CGH alterations had longer disease-free survival.
- Genetic imbalances were found in all chromosomes analyzed.
Takeaway
This study found that a specific genetic change in a type of cancer called malignant fibrous histiocytoma can help doctors predict how well patients will do after treatment.
Methodology
The study analyzed 39 cases of malignant fibrous histiocytoma using comparative genomic hybridization to identify genetic alterations and correlated these with clinical outcomes.
Limitations
The findings are based on a limited number of cases and need confirmation in larger studies.
Participant Demographics
The study included 39 patients, 20 females and 19 males, with a median age of 69 years.
Statistical Information
P-Value
P=0.001 for overall survival, P=0.004 for disease-free survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website